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Abstract. The dystrophin glycoprotein complex (DGC) is 
a multimeric protein assembly associated with either the 
X-linked cytoskeletal protein dystrophin or its autosomal 
homologue utrophin. In striated muscle cells, the DGC 
links the extracellular matrix to the actin cytoskeleton and 
mediates three major functions: structural stability of the 
plasma membrane, ion homeostasis, and transmembrane 
signaling. Mutations affecting the DGC underlie major 
forms of congenital muscle dystrophies. The DGC is 
prominent also in the central and peripheral nervous sys-
tem and in tissues with a secretory function or which form 
barriers between functional compartments, such as the 
blood-brain barrier, choroid plexus, or kidney. A consid-
erable molecular heterogeneity arises from cell-specific 
expression of its constituent proteins, notably short C-ter-
minal isoforms of dystrophin. Experimentally, the genera-
tion of mice carrying targeted gene deletions affecting the 
DGC has clarified the interdependence of DGC proteins 
for assembly of the complex and revealed its importance 
for brain development and regulation of the ‘milieu intéri-
eur’. Here, we focus on recent studies of the DGC in brain, 
blood-brain barrier and choroid plexus, retina, and kidney 
and discuss the role of dystrophin isoforms and utrophin 
for assembly of the complex in these tissues.
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Introduction
The dystrophin glycoprotein complex (DGC) comprises 
five classes of proteins (dystroglycans, syntrophins, dys-
trobrevins, sarcoglycans, and sarcospan) made of several 
members or isoforms, and assembled with either dystro-
phin or its autosomal homologue utrophin (Fig. 1). The 
DGC has been studied mainly in the context of muscle 
dystrophies and cardiomyopathies [1–3]. It is critical 
for integrity of muscle fibers by linking the actin cyto-
skeleton to the extracellular matrix (ECM) [4–8]. More 
recently, its roles as a signaling complex and as a scaf-
fold for membrane proteins have gained preeminence. 
Furthermore, the DGC has been recognized to be mo-
lecularly heterogeneous and present in numerous tissues, 
notably in the central and peripheral nervous system, and 
in tissues with secretory function or forming barriers be-
tween functional compartments, such as the blood-brain 
barrier (BBB), choroid plexus (CP), or kidney. While the 
functional role of ‘non-muscle’ DGC remains to be clari-
fied in most of these organs, there is compelling evidence 
for its involvement in brain development, synapse forma-
tion and plasticity, as well as water and ion homeostasis. 
The analysis of mice carrying spontaneous or targeted 
mutations affecting specific DGC components has clari-
fied the interdependence of DGC proteins for assembly 
of the complex. These studies have also shown that de-
spite functional redundancy, dystrophin isoforms and 
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utrophin are likely to fulfill distinct roles in non-muscle 
tissue. Here, we will briefly summarize major features of 
the DGC in skeletal muscle cells and present an overview 
of recent developments about the DGC in the brain, BBB, 
retina, and kidney. The major focus of this review is the 
role of dystrophin isoforms and utrophin for proper as-
sembly and function of the DGC in these tissues.
The DGC in skeletal muscle
The major components of the DGC have been isolated 
and characterized best in skeletal muscle cells and will 
be presented briefly (Fig. 1) before discussing their role 
and localization in ‘non-muscle’ tissue. The sarcoglycan 
complex and sarcospan, which are transmembrane pro-
teins linked to the DGC (Fig. 1), will not be considered 
in this review.
Dystrophin
The dystrophin gene, located on the X chromosome, 
spans approximately 2.5 Mb and is composed of 79 exons 
[9, 10]. Duchenne muscular dystrophy (DMD) is caused 
by mutations causing a frame-shift and abortion of pro-
tein translation. Three independently regulated promot-
ers, in muscle, brain, and specifically Purkinje cells in the 
cerebellum, control expression of full-length dystrophin 
[11–17]. In skeletal muscle, dystrophin predominates at 
the sarcolemma but is also found at the troughs of the 
postsynaptic membrane along with voltage-gated sodium 
channels [17, 18]. Several short dystrophin isoforms arise 
from differential promoter usage. Transcripts from four 
internal promoters encode proteins of 260, 140, 116, and 
71 kDa (Dp260, Dp140, Dp116, and Dp71) [19]. Dp71 
is subjected to alternative splicing of exons 71–74 and/
or 78, generating at least four Dp71 isoforms [20] with 
widespread distribution in various non-muscle tissues 
[21–32]. Full-length dystrophin binds actin near its N 
terminus and dystroglycan, thereby providing a structural 
link between the membrane and the cytoskeleton (Fig. 1). 
Dp71 also carries an actin-binding site [33], suggesting 
that this short C-terminal isoform fulfills similar func-
tions.
Utrophin
Utrophin was discovered as a cDNA isolated from fetal 
muscle with high homology to the DMD gene [34]. It is 
expressed in nearly all tissues, including skeletal muscle, 
with particularly high levels in lung, kidney, nervous sys-
tem, and vascular endothelial and smooth muscle cells 
[25, 31, 32, 35–38], but its function remains largely un-
known. Most studies have focused on adult skeletal mus-
Figure 1. Schematic organization and composition of the DGC at the neuromuscular junction. Dystrophin or utrophin bind to actin fila-
ments via their N terminus. At the C terminus, dystrophin or utrophin are associated with integral and peripheral membrane proteins that 
can be classified as the dystroglycan complex, the sarcoglycan-sarcospan complex, and the cytoplasmic complex. The cytoplasmic complex 
includes isoforms of syntrophin (α1-, β1-, β2-syn) and α-dystrobrevin. The sarcoglycan-sarcopsan complex comprises isoforms of sarco-
glycan (α, β, γ, δ) and sarcospan (SP). The extracellular component of the dystroglycan complex, α-dystroglycan (α-DG), binds to agrin 
and laminin in the extracellular matrix and the transmembrane isoform β-dystroglycan (β-DG). In turn, β-dystroglycan binds to dystrophin 
or utrophin, thus completing the link between the actin-based cytoskeleton and the extracellular matrix. Rapsyn is involved in acetylcholine 
receptor (AChR) clustering. Signaling proteins such as the microtubule-associated serine/threonine kinase (MAST) or the neuronal nitric 
oxide synthase (nNOS) are recruited to the DGC via PDZ-binding domains.
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cle, where two full-length isoforms of utrophin, differ-
ing in their initial few amino acids, have been identified 
(A- and B-utrophin) [39, 40]. Utrophin is expressed in 
several structures within skeletal muscle tissue (includ-
ing blood vessels and nerves) but the dominant utrophin 
isoform in muscle fibers is A-utrophin. It is confined to 
the neuromuscular junction (NMJ) and is closely associ-
ated with acetylcholine receptors (AChRs) at the crests of 
the postsynaptic membrane [17, 18,  41–44]. In the pres-
ent review, no further distinction will be made between 
the two full-length utrophin isoforms, which are simply 
referred to as utrophin.
Dystroglycan
Dystroglycan was the first member of the DGC to be 
cloned [45]. The dystroglycan gene, DAG1, comprises 
two exons and encodes a single polypeptide that is post-
translationally cleaved to yield two glycoproteins [46, 47]. 
Dystroglycan, which anchors the DGC to the sarcolemma 
and interacts with multiple components of the ECM, is 
a central component of the complex. Its function criti-
cally depends on multiple glycosylation sites which are 
regulated in a tissue-specific manner [48]. Full chemical 
deglycosylation of dystroglycan results in loss of ligand-
binding activity [5], and abnormal glycosylation is asso-
ciated with several congenital muscular dystrophies and 
abnormal central nervous system (CNS) development [2, 
49–51]. α-Dystroglycan (α-DG) is located extracellularly 
where it functions as a laminin/agrin receptor involved in 
basal membrane formation and synaptogenesis [52–56]. 
β-Dystroglycan (β-DG) spans the membrane and binds 
either dystrophin or utrophin at a WW domain near its C 
terminus. Caveolin 3 binds to the same domain [57], sug-
gesting a potential competitive interaction modulating the 
membrane anchoring of the DGC [58]. β-DG also binds 
rapsyn, a protein of the NMJ that is required for clustering 
of AChRs [59, 60], as well as signaling molecules, such 
as Grb2, a growth factor receptor-bound adapter protein 
[61, 62]. The concept that β-DG acts as a scaffolding pro-
tein has recently been strengthened by the demonstration 
that it binds to both MEK and ERK, thereby modulating 
the ERK-MAP signaling cascade [63].
However, the significance of dystroglycan extends far be-
yond striated muscle, as it is the most broadly expressed 
DGC component in both developing and adult tissues [2, 
64–66], typically in cell types apposed to a basal lamina 
[67]. Furthermore, dystroglycan plays an important role 
in the peripheral nervous system, regulating Schwann cell 
function and the organization of nodes of Ranvier [68, 
69]. Finally, the binding of α-DG to neurexins, neuron-
specific cell surface proteins, suggests a novel role for 
dystroglycan as an intercellular cell adhesion molecule 
in neurons [70].
Syntrophin
The syntrophin (syn) family is composed of five mem-
bers, α1-, β1-, β2-, γ 1-, and γ 2-syn encoded by different 
genes. α1, β1, β2, and γ 2 are expressed in skeletal muscle 
[71–73]. β2-syn is restricted to the NMJ, whereas α1-, 
β1-, and γ 2-syn are also localized along the sarcolemma 
[73, 74]. Accordingly, α1- and β1-syn are associated with 
dystrophin and β2-syn with utrophin [75]. Syntrophins 
are also expressed in other tissues, such as brain [26, 76–
79], retina [80, 81], kidney [32, 82, 83], and liver [84–86]. 
The γ-syntrophins are most abundant in the brain with 
γ1-syn being neuron specific [73].
Syntrophins carry a PDZ-binding domain interacting 
with a variety of signaling molecules and membrane pro-
teins (Fig. 1), including neuronal nitric oxide synthase 
(nNOS) [87], aquaporin 4 (AQP4) [88], inwardly rectify-
ing K+ channels [89], muscle voltage-gated sodium chan-
nels [77, 90], and stress-activated protein kinase 3 [91]. 
In addition, β2-syn recruits the serine/threonine kinases 
MAST and SAST to the DGC [92]. The multiple protein-
protein interactions mediated by syntrophins underscore 
the role of the DGC as a scaffold regulating surface ex-
pression of channel proteins and subcellular localization 
of signaling complexes.
Dystrobrevin
Dystrobrevin is a member of the dystrophin-related pro-
tein family with significant homology to the C terminus of 
dystrophin [93, 94]. Two isoforms, α- and β-dystrobrevin 
(α- and β-DB), are encoded by different genes [95–97]. 
The α-DB gene gives rise to at least five splice variants: 
α-DB1, -2, and -3 are present at the sarcolemma; α-DB1 
is restricted to the NMJ whereas α-DB2 has a distribu-
tion similar to that of dystrophin [97–99]. Both isoforms 
bind directly to dystrophin and utrophin through recipro-
cal coiled-coil regions in each protein [100, 101]. β-DB is 
absent from striated muscle but is expressed in many non-
muscle tissues where it associates with Dp71 and utrophin 
[26, 29]. A potential signaling molecule containing two 
MAGE homology domains has recently been identified 
which selectively binds α-DB and is colocalized with the 
DGC in brain, muscle, and peripheral nerves [102].
Mutant mice models for studying assembly and 
function of the DGC
Although no human mutations have been found in genes 
encoding dystroglycan, syntrophin or dystrobrevin [2, 
50], mouse lines carrying targeted gene deletions for 
these DGC proteins have been generated to study their 
function. These mutants are presented here in the context 
of the role and assembly of the DGC in striated muscle 
and will be discussed in more detail further on.
Cell. Mol. Life Sci.  Vol. 63, 2006 Review Article       1617
Dystrophin-null mice
mdx mice [103] lack full-length dystrophin due to a spon-
taneous point mutation in exon 23 of the DMD gene [104]. 
These mice exhibit moderate signs of skeletal muscle 
dystrophy but show little weakness and have a near nor-
mal lifespan. This mild phenotype is due in part to com-
pensatory up-regulation of utrophin [105, 106]. However, 
in the absence of dystrophin, α-DB1 and -2, as well as 
α1-, β1-, and β2-syn disappear from the sarcolemma but 
remain at the NMJ [106], where they probably associate 
with utrophin [75]. The sarcolemmal loss of α1-syn also 
affects nNOS and AQP4, which are not properly targeted 
to the membrane in mdx mice [107, 108]. Human stud-
ies have reported similar findings, showing that α1-syn, 
α-DB1, and α-DB2 were reduced in muscle from DMD 
patients [109, 110]. Despite the mild phenotype of mdx 
mice, a typical diagnostic criterion for muscular dystro-
phies remains: creatine kinase plasma levels are elevated 
in mdx mice [103].
In mdx mice, short C-terminal isoforms of dystrophin, 
such as Dp71, are not affected. Mice lacking all dys-
trophin isoforms (mdx3Cv) have been generated to over-
come this limitation [111, 112]. However, the presence 
of dystrophin-expressing ‘‘revertant’’ muscle fibers has 
been reported in both mdx and mdx3Cv mice [16], probably 
due to exon-skipping events occurring during all stages 
of development. DMDmdx-βgeo mice carry a transgene 
inserted 3′ to exon 63 of the dystrophin gene, affecting 
translation of all dystrophin isoforms, including Dp71 
[113]. These mice develop a dilated esophagus and also 
cardiac hypertrophy. Both mdx3Cv and DMDmdx-βgeo 
mice display essentially the same muscle pathology as 
mdx mice but have additional defects reflecting the loss 
of DGC in non-muscle tissue and resulting in a shorter 
lifespan.
Finally, mutant mice carrying targeted deletions of the 
DMD gene have been generated [114]. DMD-null males 
are sterile and exhibit severe degeneration and regenera-
tion of myofibers in striated muscle, as seen in DMD 
patients [114]. In contrast, mutants with a brain-specific 
inactivation of full-length dystrophin exhibited no his-
tological abnormality in striated muscle nor in various 
non-muscle tissues and were indistinguishable from their 
wild-type littermates [114]. However, a detailed behav-
ioral evaluation of these mice will be necessary to con-
firm a lack of neurological phenotype.
Utrophin-null mice
Utrophin0/0 mice have no morphological defects, breed 
normally, and have a normal lifespan [115]. Dystrophin 
expression remains unchanged at the sarcolemma but is 
up-regulated at the NMJ [116]. In contrast, β-DG and dys-
trobrevin are normally distributed in utrophin-deficient 
skeletal muscle. Morphologically, the NMJ of utrophin0/0 
mice is normal at birth but fewer postsynaptic folds de-
velop thereafter, along with a modest decrease in AChR 
density [116, 117]. Therefore, utrophin is dispensable for 
clustering of AChRs at the NMJ, although utrophin is lost 
from the NMJ in the absence of AChRs [118, 119]. In 
conclusion, utrophin appears to be dispensable for assem-
bly of a DGC but contributes to proper maturation of the 
postsynaptic apparatus [60, 117].
Utrophin-dystrophin double-knockout mice
The functional redundancy between utrophin and dystro-
phin has been confirmed in utrophin0/0/mdx double-mu-
tant mice, which show major symptoms of DMD, includ-
ing severe muscle weakness, pronounced growth retarda-
tion as well as reduced lifespan [120]. In addition, β-DG 
is down-regulated, whereas dystrobrevin and β2-syn are 
undetectable at the NMJ. Nonetheless, laminin-β2, agrin, 
and rapsyn are unaffected at synapses of utrophin0/0/mdx 
mice, indicating that postsynaptic differentiation can oc-
cur not only in the absence of both utrophin and dystro-
phin but also when the DGC is largely disrupted [120]. 
However, a compensation by dystrobrevin or dystrophin-
related protein 2 [121] has not been excluded in these 
mice.
Syntrophin- and dystrobrevin-null mutations
In α1-syn0/0 mice, β1- and β2-syn are up-regulated 
whereas utrophin is lost from the NMJ, suggesting a 
mandatory association [75, 122]. In addition, AChRs and 
ACh esterase are significantly decreased, whereas nNOS 
is absent from the postsynaptic membrane and the sar-
colemma [122]. Mice lacking β2-syn have no apparent 
muscle phenotype, except for elevated AChR number at 
the NMJ [123]. That the absence of this protein, which 
binds to several signaling molecules, does not cause a 
more severe phenotype is surprising. Even in mice lack-
ing both of these syntrophin isoforms there is no evidence 
of muscle dystrophy although they run significantly less 
on voluntary exercise wheels than wild-type mice of either 
parent strain [123]. In the absence of damage to muscle 
fibers, this deficit may be due to an unrelated defect, per-
haps affecting metabolism or neuronal function. Analysis 
of the NMJ of α1/β2-syn-null mice has revealed struc-
tural defects similar in nature but more severe than those 
observed in the α1-syn0/0 mice. These alterations occurred 
despite the presence of normal levels of dystrophin, dys-
trobrevin, and sodium channels [123]. Altogether, these 
observations point to extensive functional redundancy 
between α1- and β2-syn.
Analysis of α-DB0/0 mice has revealed a dual role for α-
DB in the pathogenesis of muscle dystrophy and in AChR 
stabilization at the NMJ [124, 125]. These mice develop 
a mild form of dystrophy without disruption of the DGC 
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at the sarcolemma, indicating that dystrophy might also 
develop as a result of impaired DGC-dependent signal-
ing. α-DB may be part of a scaffolding or signaling com-
plex required to assemble components of the postsynap-
tic membrane during synapse formation [126]. Finally, 
mice lacking β-DB do not suffer from dystrophy since 
this isoform is not expressed in skeletal muscle. Never-
theless, the DGC is altered at the membrane of cortical 
renal tubules and hepatic sinusoids [82], underscoring the 
importance of β-DB in non-muscle tissues.
Mutations affecting dystroglycan
Dystroglycan is essential for embryonic development, 
as reflected by disruption of the Reichert’s membrane 
surrounding the embryo, resulting in early lethality of 
null mutant mice [65]. In vitro, embryonic stem cells of 
DAG1-null mice form embryoid bodies with a disrupted 
basement membrane. However, when allowed to differen-
tiate further, these cells can give rise to skeletal muscle, 
cardiac muscle, and neurons [127]. Furthermore, chi-
meric mice are rescued from early embryonic lethality 
and exhibit normal striated muscle differentiation [127]. 
These mice have severely reduced levels of utrophin and 
AChRs at the NMJ, confirming the critical role of dystro-
glycan in the formation of the NMJ [47].
Importantly, dystroglycan function is severely impaired 
by glycosylation defects. Mutations in at least six genes 
encoding glycosylation enzymes are associated with 
congenital muscular dystrophies or myopathies [51, 
128–132] commonly termed dystroglycanopathies [50]. 
The mutations are associated with hypoglycosylation 
of α-DG and concomitant loss of binding to laminin, 
agrin, neurexin, or perlecan [133–137]. For instance, the 
Large gene, which encodes a putative bifunctional gly-
cosyltransferase, is mutated in the myodystrophy (myd) 
mouse [133] and in congenital muscular dystrophy type 
1D (MDC1D) [138]. myd mice exhibit deficits in neu-
ronal migration (lissencephaly), runting, an abnormal 
gait, cardiomyopathy, and have a shortened lifespan. 
Surprisingly, dystrophin and other DGC members are 
still present at the sarcolemma of muscle cells devoid of 
dystroglycan [139, 140], suggesting alternative mecha-
nisms for membrane anchoring of the DGC [50]. The 
significance of dystroglycanopathies in the brain will 
be discussed below.
Altogether, the results summarized in this section show 
that muscle dystrophies are associated with loss-of-func-
tion mutations independently affecting multiple members 
of the DGC. The phenotype of most animal models is 
not identical to that of patients with congenital muscle 
dystrophies, probably due to the complex, tissue-specific 
roles assumed by the DGC. These results also show that 
the function and assembly mechanisms of the DGC in 
skeletal muscle cells cannot be generalized to non-mus-
cle tissues because most functions depend on partner pro-
teins with a cell-specific distribution and regulation.
The DGC in non-muscle tissues
In striated muscle cells, three major functional domains 
can be distinguished in the DGC: (i) the actin-binding 
domain of utrophin or dystrophin which links the com-
plex to the cytoskeleton; (ii) the transmembrane protein 
β-DG and its peripheral isoform α-DG which anchor the 
DGC to the cell membrane and provide contact with the 
ECM; (iii) the binding sites to signaling proteins located 
on β-DG, syntrophin, and dystrobrevin. In non-muscle 
tissues, the DGC typically contains fewer components as-
sociated with a short C-terminal isoform of dystrophin, 
such as Dp71 or with utrophin, although the failure to 
detect some DGC members may be due to technical limi-
tations. Nevertheless, the DGC is usually concentrated at 
membranes facing a basal lamina, suggesting an impor-
tant signaling function, and its components carry binding 
sites for membrane channels or transporters. Below, we 
review recent developments in the molecular composi-
tion, localization, and functional role of the DGC in four 
major organs and tissues: brain, BBB and CP, retina, and 
kidney, in which the DGC has been characterized exten-
sively in mutant mice.
Brain
Studies of the DGC in brain have addressed mainly its 
role in mediating brain abnormalities and mental retarda-
tion affecting numerous patients with congenital muscle 
dystrophies, as well as its role in synapse formation and 
plasticity [141–146]. Members of the DGC are present 
in specific neurons, astrocytes, and radial glia [19, 23, 
26, 30, 35, 37, 64, 145, 147–155], usually associated 
with either dystrophin isoforms or with utrophin. Thus, 
full-length dystrophin is neuron specific and is present 
in the hippocampus, cerebral cortex, and cerebellum, as-
sociated with dystroglycan, as well as dystrobrevin and 
syntrophins [26, 76, 151, 156, 157]. Dp140 is present se-
lectively in the CNS and kidney and is particularly highly 
expressed prenatally; it is distributed primarily in astro-
cytic processes, outlining blood vessels and in the menin-
ges [158]. Dp71 is present in dentate gyrus granule cells 
and in the olfactory bulb [23, 159] and is predominantly 
found in astrocytes (see below). Utrophin has a distribu-
tion in neurons largely complementary to dystrophin, be-
ing highly abundant in brainstem [37]. Moreover, utro-
phin is highly expressed in brain microvessel endothelial 
cells (see below).
Dystroglycan has a widespread distribution in the brain, 
including regions lacking dystrophin and utrophin [64, 
155]. Besides its distribution in neurons with other DGC 
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members, dystroglycan is highly abundant in astrocytes, 
such as the Bergman glia [151, 160] and glial limitans [49, 
135]. In neurons, the DGC is localized postsynaptically at 
inhibitory synapses, colocalizing with GABAA receptors 
[153, 157, 158]. However, other studies have shown that 
dystrophin, β-DB, and syntrophins are enriched in prepa-
rations of postsynaptic densities (PSDs) [147, 161, 162], 
suggesting that both inhibitory and excitatory synapses 
might contain a DGC. The functional significance of the 
DGC in PSDs is further underscored by the binding of 
nNOS to α1-syn [78, 87]. In turn, nNOS binds to PSD-93 
and PSD-95, which are involved in N-methyl D-aspartate 
(NMDA) receptor clustering [87]. Therefore, the DGC 
might recruit nNOS in excitatory synapses, where it is 
activated by NMDA-receptor-mediated Ca2+ influx. This 
hypothesis is further supported by the demonstration that 
nNOS mRNA expression depends on dystrophin in cul-
tured human neurons [163].
To understand whether alterations in the DGC in neurons 
underlie cognitive impairments in DMD patients, mdx 
mice have been extensively studied for defects of neuro-
nal function. At the morphological level, the absence of 
full-length dystrophin is accompanied by impaired syn-
aptic clustering of GABAA receptors [153], suggesting a 
role for dystrophin in regulating GABAergic transmis-
sion in a subset of inhibitory synapses. Thus, this deficit 
has been associated with a reduction in inhibitory trans-
mission in Purkinje cells [164] and with altered short- 
and long-term synaptic plasticity in CA1 pyramidal cells 
[165, 166]. While some studies have observed no im-
pairment in spatial learning or long-term potentiation in 
the absence of dystrophin [167, 168], a reassessment of 
mdx mice has revealed altered long-term retention, but 
not acquisition in both spatial and non-spatial learning 
tasks [166]. mdx3Cv mice show enhanced anxiety-related 
behaviors and reduced locomotion but are otherwise no 
more impaired than mdx mice in learning and memory 
tasks [169], which is in line with the predominant ex-
pression of full-length dystrophin in hippocampal pyra-
midal cells.
Pathological studies of brains of DMD patients with cog-
nitive impairments have shown reductions in brain weight, 
preferential loss of neuronal populations that normally 
express dystrophin, and small cortical ischemic infarcts 
[141], suggesting that the absence of dystrophin increases 
neuronal susceptibility against hypoxia-induced injury. 
In line with this hypothesis, CA1 pyramidal neurons in 
a hippocampal slice preparation of mdx mice have been 
found to be more vulnerable to hypoxia [170] and could 
be protected by pretreatment with diphenylhydantoin, an 
anticonvulsant that blocks both sodium-dependent action 
potentials and low-threshold transient calcium channels. 
This increased neuronal vulnerability might contribute to 
the development of cognitive deficits in DMD patients 
[170].
The role of utrophin in brain is not known. Interestingly, 
unlike in muscle cells, utrophin is not aggregated at post-
synaptic sites but is localized along the membrane of 
neuronal somata and proximal dendrites [37], suggest-
ing that its function is unrelated to synaptic transmission. 
A potential neuroprotective role of utrophin has been 
uncovered in a mouse model of temporal lobe epilepsy 
induced upon unilateral injection of kainic acid into the 
dorsal hippocampus of adult mice [171], and in which ex-
tensive dispersion and hypertrophy of granule cells occur 
in the dentate gyrus. These changes are accompanied by 
a prominent overexpression of utrophin in granule cells 
[159]. Utrophin0/0 mice exhibit an increased sensitivity 
to kainate-induced excitotoxicity, as shown by increased 
mortality and faster progression of the lesion [172] and a 
significant reduction in the number of hypertrophic gran-
ule cells, suggesting that utrophin contributes to protect 
these neurons against pathological insults, in particular 
stimuli leading to cellular hypertrophy [172].
By far the major functional contribution of the DGC in 
brain is assumed by dystroglycan, as revealed by the pro-
found brain malformations occurring in muscle-eye-brain 
disease and in Fukuyama congenital muscular dystrophy 
[173, 174], two congenital muscle dystrophies associated 
with α-DG loss of function due to mutations in glycosyl-
ation enzymes [135]. Similar brain malformations could 
be reproduced experimentally in myd mice [135] and in 
mutant mice with a brain-specific deletion of DAG1 un-
der the control of an astrocyte-specific promoter [49], 
demonstrating that dystroglycan requires glycosylation 
for proper function and is essential for regulating cell mi-
gration and differentiation during development, as well 
as synaptic plasticity in adult brain. In the brain of myd 
mice, other members of the DGC, including dystrophin, 
were not targeted appropriately to postsynaptic sites and 
to glial endfeet [135], underscoring the role of dystrogly-
can-mediated function for this process, unlike in striated 
muscle cells. Despite this deficit, dystroglycan-deficient 
neurons in culture form synapses containing GABAA re-
ceptors and gephyrin clusters opposite GABAergic termi-
nals [158], indicating that the DGC is not required for the 
development of these synapses.
Altogether, these findings reveal that the DGC expressed 
in cells of the astrocytic lineage plays an essential role 
during brain development, whereas the neuronal DGC, 
which is localized selectively in specific subsets of syn-
apses in adult brain, most likely modulates synaptic func-
tion and plasticity, and might be neuroprotective against 
ischemic damage and other stimuli leading to hyper-
trophy. This conclusion is in line with reports that full-
length dystrophin expression becomes detectable during 
the third postnatal week in rodents [37], after neuronal 
migration and synaptogenesis are largely completed. The 
reason why the DGC is restricted to specific neuronal 
populations in the brain is open to speculation.
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BBB and CP
Endothelial cells of brain microvessels form the BBB, 
thereby contributing to the protection of the brain against 
variations in the chemical composition of the blood 
[175]. Astrocytes contribute to the formation of the BBB 
during development by inducing tight junctions between 
endothelial cells [176]. Brain vessels, including capillar-
ies, are a prominent site of expression of DGC proteins, 
expressed in both endothelial cells and astrocytic endfeet 
[26, 37, 79, 177–179]. In addition, DGC proteins are also 
present in the CP [31], suggesting a potential role in wa-
ter homeostasis and regulation of transport mechanisms 
across the BBB, as well as cerebrospinal fluid produc-
tion.
Utrophin is abundantly expressed along with β2-syn in 
brain endothelial cells [31, 37] but not in astrocytic end-
feet (Fig. 2) [31]. In these studies, no other DGC mem-
ber protein, including Dp71 and dystroglycan, has been 
detected in endothelial cells of brain capillaries, unlike 
previous reports describing the presence of dystrogly-
can in brain blood vessels [96, 155]. The discrepancy 
between these results might reflect a possible heteroge-
neity between capillaries and arterioles. In any case, the 
molecular composition of the DGC in endothelial cells 
appears to be simpler than in striated muscle or in neu-
rons.
No β2-syn immunoreactivity is detectable in brain blood 
vessels from utrophin0/0 mice, demonstrating a direct as-
sociation of these proteins in endothelial cells [31], as in 
striated muscle. However, the loss of utrophin and β2-syn 
did not affect the localization of the MRP2-type of ABC 
transporter or the glucose transporter 1 (GLUT1), which 
are present in the luminal membrane of endothelial cells 
in the brain [31]. So far, we do not know whether specific 
signaling proteins or transporters are associated with the 
DGC in endothelial cells. No alteration in staining for 
utrophin and β2-syn could be observed in brain blood ves-
sels of mdx3Cv mice [31], in agreement with the absence 
of detectable Dp71 in endothelial cells of wild-type mice 
(Fig. 2). However, the absence of Dp71 from astrocytic 
endfeet (see below) during development has been sug-
gested to affect the development of the BBB, leading to 
an altered expression of the tight junction marker zonula 
occludens 1 (ZO-1) in old mdx mice [180]. These authors 
therefore speculate that altered cross-talk between glial 
endfeet and endothelial cells in the absence of dystrophin 
might contribute to the neurological dysfunctions associ-
ated with DMD [181].
Astrocytic endfeet surrounding brain blood vessels ex-
hibit prominent Dp71 expression (Fig. 2) along with β-
DG, syntrophin isoforms, and α-DB1 [26, 31, 182–184]. 
High-resolution immunoelectron microscopy studies have 
demonstrated that AQP4 and the inwardly rectifying K+ 
channel, Kir4.1, are localized selectively in the astrocytic 
membrane that is in direct contact with the basal lamina 
facing the blood vessel [179, 185–187]. Both proteins 
bind to the PDZ domain of α1-syn [185], suggesting that 
the DGC anchors these proteins at the membrane. The 
importance of this association has been demonstrated 
in α-syn0/0 mice, in which the membrane localization of 
AQP4 and Kir4.1 is disrupted, causing a delay in clear-
ance of extracellular K+ after neuronal activation and an 
increase in seizure susceptibility [178, 185, 188, 189].
In mdx3Cv mice, no DGC proteins can be detected at peri-
vascular endfeet of astrocytes [31], suggesting a complete 
disruption of the DGC affecting also the localization of 
AQP4 [190]. However, earlier studies reported that syn-
trophin, dystrobrevin, and dystroglycan were not altered 
in these mice [26, 112]. While these discrepancies might 
reflect incomplete penetrance of the mutation, expression 
of DGC proteins, as detected by Western blotting, may 
remain unaltered in mutant mice even when their local-
ization is disrupted.
In CP epithelium, a DGC distinct from those found in 
brain microvessels has been described [31, 37, 191]. It 
is formed by utrophin along with β1- and β2-syn and 
β-DB [31]. Unexpectedly, β-DG was not detected in CP 
epithelial cells, whereas α-DG was targeted apically [31] 
despite the presence of a basal lamina between the epi-
thelial cells and the underlying endothelium. Therefore, 
it remains unclear how the DGC is anchored at the epithe-
lial cell membrane and whether it is linked to the ECM. In 
CP of utrophin0/0 mice, β1- and β2-syn were undetectable 
whereas β-DB was mislocalized to an intracellular com-
partment, suggesting that these proteins are differentially 
dependent on utrophin for proper membrane targeting 
[31]. These alterations had no apparent consequences 
for the morphology of epithelial cells, although no com-
pensation by full-length dystrophin or Dp71, which are 
normally not detectable in the CP, could be observed in 
utrophin0/0 mice [31].
Taken together, these observations suggest the presence 
of at least three distinct DGCs in the BBB and CP. The 
analysis of mutant mice shows a clear dependence of 
DGC proteins for the presence of either Dp71 or utro-
phin for proper assembly of the complex, and provides 
no evidence for compensatory up-regulation of another 
member of the DGC. While the function of the DGC at 
the BBB and in the CP remains to be uncovered, its role as 
a scaffold for membrane anchoring of AQP4 and Kir4.1 
channels is well established in astrocytic endfeet.
Retina
In analogy to the brain, multiple molecularly distinct 
DGCs are found in the retina, notably in photoreceptors, 
neurons, Muller glial cells (MGCs), and blood vessels 
[192–194]. The predominant dystrophin isoforms are full-
length dystrophin, Dp260, Dp140, and Dp71; utrophin is 
also present, mainly at the same sites as Dp71 [195–200]. 
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In the outer plexiform layer (OPL), where photoreceptors 
form synapses with horizontal and bipolar cells, the DGC 
contains dystrophin, dystroglycan, α1-syn, and α-DB 
[80, 199, 201]. The organization of the DGC differs from 
that of other neurons, being localized presynaptically in 
photoreceptor terminals [197, 198, 202–207]. Possible 
species differences exist, with both a pre- and a postsyn-
aptic DGC being present in the OPL of rabbit and porcine 
retina [81, 207]. A DGC of similar composition is found 
also at the IPL (synapses between bipolar/amacrine cells 
and ganglion cells), although α-DG was not detectable 
[199]. In contrast, an atypical DGC is found at the outer 
segment (OS) of photoreceptors, containing β-DG and 
α1-syn but lacking either dystrophin or utrophin [199].
A major DGC is present in the inner retina where MGC 
endfeet join to form the inner limiting membrane (ILM), 
separating the retina from the vitreous body. Across this 
barrier, K+ ions are released into the vitreal space through 
Kir4.1 channels, which are concentrated at the MGC 
endfeet [208], contributing to K+ buffering [209]. In ad-
dition, AQP4 is localized at the perivascular membrane 
of MGC endfeet [210] to control retinal water transport 
[211]. Several members of the DGC have been detected 
in MGCs (β-DG, α1-, β1-syn, α-DB) and their endfeet 
(Dp71, utrophin, dystroglycan) [28, 199–201, 208, 212]. 
The complex associates with Kir4.1 and AQP4, similar 
to the DGC found in perivascular astrocytic endfeet in 
brain, and most likely fulfills a similar functional role 
[213].
The segregation of various DGCs to different retinal lay-
ers has allowed detailed analyses of the role of dystrophin 
isoforms for their assembly and subcellular localization. 
For example, in retina of mdx3Cv mice, β-DG protein levels 
are reduced in the ILM and OPL [199], whereas α1-syn 
and α-DB are not affected [199]. Furthermore, clustering 
of Kir4.1 is disrupted in MGC endfeet of mdx3Cv [208]; 
unexpectedly, it is not affected in α1-syn0/0 mice [212], 
pointing to a differential mechanism compared with brain 
blood vessels. Partial disruption of the DGC has also been 
reported in the retina of Dp71-null mice, which exhibit 
reduced levels of β-DG at the ILM, whereas α1-syn is 
Figure 3. Differential expression and cellular distribution of utrophin in mouse kidney. A schematic drawing of the nephron is depicted 
on the right panel. The cortical and medullary thick ascending limbs are colored in red. Low-resolution immunofluorescence images (left 
panel) depict utrophin (green) distribution in the cortex and medulla. In the cortex, utrophin staining is heterogeneous, labeling glomeruli 
and few cortical segments. Using a renal segment-specific marker, the Na+/K+/Cl– cotransporter 2 (NKCC2) (red, right panel), which is 
polarized along the apical membrane of cortical and medullary thick ascending limbs, we could identify a utrophin-positive segments. In 
the medulla, utrophin exhibits a homogenous distribution and double staining with NKCC2 revealed medullary thick ascending limbs as 
utrophin-positive segment (lower middle panel). More renal markers have been investigated [32]. Scale bars, 200 μm (utrophin), 30 μm 
(NKCC2).
Figure 2. Segregated distribution of utrophin (green) and Dp71 
(red) at the BBB and in astrocytic endfeet (GFAP-staining, blue). A 
schematic representation of a blood vessel surrounded by endfeet is 
depicted on the left. Utrophin immunoreactivity is localized in en-
dothelial cells, whereas Dp71 overlaps with the GFAP signal in glial 
endfeet forming a ring around the blood vessel. Scale bar, 5 μm.
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not affected [200]. Unlike in mdx3Cv mice, β-DG expres-
sion is normal at the OPL, possibly due to association 
with Dp260 [200]. Therefore, Dp71 is important for the 
assembly of the DGC selectively in MGC endfeet. This 
conclusion is supported by the fact that β-DG is disrupted 
at the OPL of mice lacking full-length dystrophin and 
Dp260 [214, 215].
The retina also provides a functional read-out applicable 
for both mutant mice and DMD patients. Indeed, electro-
retinogram (ERG) anomalies are among the best-charac-
terized non-muscular manifestations of DMD. Analysis 
of the dark-adapted ERG has revealed a reduction in the 
amplitude of the b-wave response in 80% of DMD pa-
tients [216–219]. A prolonged implicit time of the b-wave 
has been observed in ERG of mice lacking full-length 
dystrophin and Dp260 [215], whereas Dp71-null mice 
showed no significant change [200]. By comparing ERG 
alterations in patients with distinct mutations, Pillers et 
al. [220] suggested that in addition to Dp260, other C-
terminal isoforms contribute to the generation of the b-
wave. This hypothesis was confirmed by the demonstra-
tion that mdx3Cv have b-waves with reduced amplitude and 
increased implicit time [221].
As expected from studies in the brain, myd mice exhibit 
major morphological alterations in the retina, affecting 
MGCs as well as neurons. A similar phenotype was seen, 
in addition, in a novel mutant mouse line, Largevls mice 
[134, 222]. These mice carry a mutation in a new allele 
of Large, named veils (vls), and share phenotypic char-
acteristics with the myd mutation [222]. These findings 
confirm that defective dystroglycan glycosylation con-
tributes to retinal abnormalities.
Kidney
Epithelial cells in the nephron express numerous DGC 
proteins, forming several distinct DGCs. As the nephron 
is organized in distinct segments to sequentially reab-
sorb ions and solutes from the glomerular ultrafiltrate, 
it represents an attractive organ to study the localization 
and specific distribution of DGC proteins [29, 32, 66, 
223–225]. Dystroglycan is expressed early by epithelial 
cells in the developing kidney, whereas in adult tissue 
only low levels are detectable [66, 67], suggesting that 
dystroglycan is more important for morphogenesis of 
renal epithelial cells than during the adult stage. Simi-
larly to dystroglycan, Dp140 is only expressed during 
kidney development [226]. Low levels of Dp71 are de-
tectable in adult kidney [32, 82, 224, 226–230], although 
a specific splice variant has been reported to be abun-
dant, in particular in the cortex [29]. In contrast, utro-
phin is prominent in all segments of the nephron except 
proximal tubules (Fig. 3) [32]. On the subcellular level, 
utrophin is specifically localized along the basal, but not 
lateral, membrane of tubular epithelial cells, demonstrat-
ing that it is restricted to sites of contact with the basal 
lamina (Fig. 3). In contrast, the DGC is polarized along 
the basolateral membrane of cultured kidney epithelial 
cells [231], suggesting altered targeting in vitro in the 
absence of the basal lamina. Using specific markers to 
identify distinct segments of the nephron, utrophin has 
been shown to be associated with different members 
of the DGC in a segment-specific manner (Fig. 3). In 
particular, α1- and β1-syn have a restricted distribution, 
whereas β2-syn and β-DB are ubiquitous [29, 32]. These 
findings indicate that Dp71 isoforms and utrophin are 
the major partners of the DGC in the nephron and that 
the functional specialization of the tubule is reflected in 
the segment-specific distribution of certain DGC pro-
teins.
Possible alterations in DGC assembly and targeting have 
been investigated in mdx3Cv mice to test the role of Dp71. 
β2-syn staining was altered in cortical renal tubules, 
Bowman’s capsule and glomeruli, whereas the localiza-
tion of β-DB, α-DB-1, utrophin, α1-syn and β1-syn was 
not affected [29]. These findings suggest differential de-
pendence of β2-syn and other DGC proteins on Dp71 
for complex formation. In a complementary study using 
utrophin0/0 mice, we have demonstrated that β2-syn local-
ization is not impaired in cortical segments in the absence 
of utrophin, whereas it is lost in all segments express-
ing high utrophin levels in wild-type mice [32]. Again, 
other DGC proteins were either not affected in mutant 
mice (β1- and α1-syn) or were upregulated (Dp71, β-DG, 
and dystrobrevin) (Fig. 4), indicating that compensatory 
mechanisms are activated to preserve most of the DGC in 
either mdx3Cv or utrophin0/0 mice [32].
To directly demonstrate this compensatory up-regula-
tion, utrophin-deficient mice were cross-bred with mdx3Cv 
mice to generate utrophin0/0/mdx3Cv double mutants. These 
mice have a reduced lifespan [120], and only few reach 
the adult stage. Nevertheless, analysis of the nephron has 
revealed a complete disruption of the DGC, highlighting 
the functional redundancy between utrophin and dystro-
phin in cells coexpressing both proteins [32].
The complex, segment-specific molecular organization 
of the DGC in the nephron suggests multiple functional 
roles related to ion transport mechanisms. In analogy to 
skeletal muscle cells, where the DGC provides membrane 
stability during muscle contractions [4], renal epithelial 
cells might also have a DGC to resist the high osmotic 
pressure of the hypertonic interstitial fluid surrounding 
medullary tubules [232]. The high abundance of utrophin 
in these segments of the nephron, unlike in the renal cor-
tex, supports this idea. Although Dp71 is upregulated in 
utrophin0/0 mice, the compensation is only partial because 
β2-syn is lost from the DGC. The reduced life expectancy 
of double-mutant mice where no compensation is possible 
in the kidney might be due to renal dysfunction. However, 
this hypothesis remains to be tested.
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Finally, for proper function of renal epithelial cells, ion 
channels, exchangers, and transporters must be targeted 
to either the apical or basolateral membrane [233]. The 
DGC may be involved in anchoring renal transporters 
and channels to the basal membrane. So far, however, no 
protein has been identified for which the DGC serves as 
a scaffolding protein, similarly to AQP4 and Kir4.1 in as-
trocytes.
Conclusions
The characterization of the DGC in non-muscle tissues 
has revealed an unexpected heterogeneity in molecular 
composition, in particular with respect to the presence 
of α- or β-DG. The mechanism of membrane anchoring 
and/or communication with the ECM is therefore not es-
tablished for some prominent DGCs, such as those seen 
in microvascular endothelial cells and the CP. However, 
negative results are not necessarily conclusive, and the 
failure to detect dystroglycan in some tissues might be 
due to technical reasons. Furthermore, some biochemi-
cal methods are of limited use in heterogeneous tissues 
with a cell-specific expression of DGC proteins. It is 
important to note that in neurons and astrocytes, as well 
as kidney tubular epithelial cells, the localization of the 
DGC precisely matches the presence of a basal lamina, 
suggesting that communication with the ECM via α-DG 
is essential for specifying the subcellular localization of 
the DGC. This feature might, for example, explain the 
Figure 4. Molecular composition of the DGC in four tissues of wild-type and either utrophin0/0 or mdx3Cv mice. Note the mandatory as-
sociation of β2-syn with utrophin in kidney, CP, and endothelial cells. In utrophin0/0 kidney, the DPC is partially rescued by compensatory 
upregulation of Dp71, but it is unclear whether it binds the actin cytoskeleton. In blood vessels (endothelial and glial endfeet), no com-
pensation occurs and the DPC is disrupted, along with AQP4. An intermediate situation occurs in the CP, where β-DB is partially retained, 
possibly due to upregulation of dystrophin-related protein 2 (DRP2).
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remarkably specific targeting of the DGC in astrocytic 
endfeet. In the CP, the DGC is present basolaterally in 
epithelial cells, arguing against the presence of dystro-
glycan in this tissue.
The analysis of mutant mice has revealed that in all cell 
types coexpressing a dystrophin isoform with utrophin, 
compensatory up-regulation takes place in the absence of 
the homologue protein (Fig. 4), obscuring the interpreta-
tion of the analysis of single mutant mice. In contrast, 
these compensatory mechanisms do not take place in tis-
sues expressing only dystrophin (glial endfeet) or only 
utrophin (CP epithelial cells, vascular endothelial cells). 
The analysis of double-mutant mice lacking dystrophin 
and utrophin is hampered by the severe phenotype, lim-
ited breeding capacity, and reduced life expectancy of 
these animals.
A major convergent finding emerging from the analysis 
of the DGC in non-muscle tissue is that syntrophins re-
quire the presence of either dystrophin or utrophin for 
assembly of the DGC and membrane localization. Owing 
to the presence of several ‘simple’ DGCs containing a re-
duced number of proteins, a mandatory association of β2-
syn with utrophin, as well as α-DB, α1-syn, and β1-syn 
with dystrophin, has been demonstrated in three distinct 
tissues (Fig. 4). The role of β-DB is less clear since it does 
not disappear from the CP of utrophin0/0 mice and associ-
ates with Dp71 in the absence of utrophin in the kidney. 
Therefore, although dystroglycan is a key member of the 
DGC, interacting with signaling proteins, dystrophin and 
utrophin appear to be essential for the formation of the 
complex, with very few exceptions so far [234].
Several membrane-associated proteins have been iden-
tified, notably AQP4 and Kir4.1, which depend on the 
DGC for proper targeting and localization. However, no 
generalization is possible since major transporters, such 
as members of the ABC transporter or the glucose trans-
porter families, which colocalize with the DGC in several 
tissues, are not affected in mutant mice. It is therefore dif-
ficult to predict functional deficits that might arise from 
an altered expression of DGC proteins. However, the ex-
istence of functional redundancy between dystrophin iso-
forms, dystrobrevin, and utrophin might represent a strong 
stimulus for exploiting further compensatory mechanisms 
to alleviate the symptoms of muscle dystrophy.
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